Overview

Crossover Trial of AD036 in Obstructive Sleep Apnea

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, 3-Period, Placebo-Controlled, Crossover, phase 2 clinical study to examine the efficacy and safety of AD036 versus placebo or atomoxetine in patients with obstructive sleep apnea.
Phase:
Phase 2
Details
Lead Sponsor:
Apnimed
Treatments:
Atomoxetine Hydrochloride